113 related articles for article (PubMed ID: 37401481)
1. CDH1 hypermethylation: a potential molecular pathway for invasiveness in glioblastoma.
Belut DR; Lima EO; Zanini MA; Galvani AF; Furtado FB; Ferrasi AC
Eur J Cancer Prev; 2024 Jan; 33(1):73-btii. PubMed ID: 37401481
[TBL] [Abstract][Full Text] [Related]
2. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas.
Qian ZR; Sano T; Yoshimoto K; Asa SL; Yamada S; Mizusawa N; Kudo E
Mod Pathol; 2007 Dec; 20(12):1269-77. PubMed ID: 17873891
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CDH1 Gene Hypermethylation Status in Blood and Serum among Gastric Cancer Patients.
Li Z; Guo Z
Pathol Oncol Res; 2020 Apr; 26(2):1057-1062. PubMed ID: 30989488
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of expression level and methylation profile of
Mohammadi Z; Azad M; Foroughi F; Khojastehpour S; Gheibi N; Samiee-Rad F; Maali A; Ahmadi MH
J Cancer Res Ther; 2021; 17(6):1328-1334. PubMed ID: 34916361
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
7. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.
Ling ZQ; Li P; Ge MH; Zhao X; Hu FJ; Fang XH; Dong ZM; Mao WM
Int J Mol Med; 2011 May; 27(5):625-35. PubMed ID: 21373750
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.
Leal M; Lima E; Silva P; Assumpção P; Calcagno D; Payão S; Burbano RR; Smith M
World J Gastroenterol; 2007 May; 13(18):2568-74. PubMed ID: 17552003
[TBL] [Abstract][Full Text] [Related]
11. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer.
Graziano F; Arduini F; Ruzzo A; Bearzi I; Humar B; More H; Silva R; Muretto P; Guilford P; Testa E; Mari D; Magnani M; Cascinu S
Clin Cancer Res; 2004 Apr; 10(8):2784-9. PubMed ID: 15102685
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma.
Marsit CJ; Posner MR; McClean MD; Kelsey KT
Cancer; 2008 Oct; 113(7):1566-71. PubMed ID: 18711702
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor.
Shargh SA; Sakizli M; Khalaj V; Movafagh A; Yazdi H; Hagigatjou E; Sayad A; Mansouri N; Mortazavi-Tabatabaei SA; Khorram Khorshid HR
Med Oncol; 2014 Nov; 31(11):250. PubMed ID: 25260805
[TBL] [Abstract][Full Text] [Related]
14. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
[TBL] [Abstract][Full Text] [Related]
15. Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors.
Lombaerts M; Middeldorp JW; van der Weide E; Philippo K; van Wezel T; Smit VT; Cornelisse CJ; Cleton-Jansen AM
Biochem Biophys Res Commun; 2004 Jun; 319(2):697-704. PubMed ID: 15178462
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma.
Xia L; Hu Y; Gu T; Wang L; Tian Z
Int J Oncol; 2018 Feb; 52(2):496-504. PubMed ID: 29207084
[TBL] [Abstract][Full Text] [Related]
17. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation Status of E-Cadherin Gene in Gastric Cancer Patients in a High Incidence Area.
Rashid H; Alam K; Afroze D; Yousuf A; Banday M; Kawoosa F
Asian Pac J Cancer Prev; 2016; 17(6):2757-60. PubMed ID: 27356686
[TBL] [Abstract][Full Text] [Related]
19. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas.
Oue N; Motoshita J; Yokozaki H; Hayashi K; Tahara E; Taniyama K; Matsusaki K; Yasui W
J Pathol; 2002 Sep; 198(1):55-9. PubMed ID: 12210063
[TBL] [Abstract][Full Text] [Related]
20. Frequent promoter methylation of CDH1 in non-neoplastic mucosa of sporadic diffuse gastric cancer.
Lee KH; Hwang D; Kang KY; Lee S; Kim DY; Joo YE; Lee JH
Anticancer Res; 2013 Sep; 33(9):3765-74. PubMed ID: 24023308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
